These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21537380)

  • 1. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.
    Saloustros E; Androulakis N; Vamvakas L; Mavroudis D; Georgoulias V
    Case Rep Oncol; 2010 Oct; 3(3):368-71. PubMed ID: 21537380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive bevacizumab-associated renal thrombotic microangiopathy.
    Uy AL; Simper NB; Champeaux AL; Perkins RM
    NDT Plus; 2009 Feb; 2(1):36-9. PubMed ID: 25949282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotic syndrome after bevacizumab: case report and literature review.
    George BA; Zhou XJ; Toto R
    Am J Kidney Dis; 2007 Feb; 49(2):e23-9. PubMed ID: 17261417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of Anti-vascular Endothelial Growth Factor Therapy-Related Nephrotic Syndrome With Marked Intraglomerular Macrophage Infiltration.
    Obara S; Inoue T; Watanabe Y; Hamaguchi T; Ikezawa T; Amano H; Ishizawa K; Okada H
    Cureus; 2023 Dec; 15(12):e50496. PubMed ID: 38222188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
    Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
    BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
    Hanna RM; Lopez EA; Hasnain H; Selamet U; Wilson J; Youssef PN; Akladeous N; Bunnapradist S; Gorin MB
    Clin Kidney J; 2019 Feb; 12(1):92-100. PubMed ID: 30746134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
    Launay-Vacher V; Janus N; Beuzeboc P; Daniel C; Ray-Coquard I; Selle F; Rey JB; Jouannaud C; Spano JP; Thery JC; Morere JF; Goldwasser F; Mir O; Oudard S; Scotté F; Dorent R; Ludwig L; Deray G; Gligorov J
    Bull Cancer; 2015 Nov; 102(11):906-14. PubMed ID: 26603517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report.
    Toriu N; Sekine A; Mizuno H; Hasegawa E; Yamanouchi M; Hiramatsu R; Hayami N; Hoshino J; Kawada M; Suwabe T; Sumida K; Sawa N; Takaichi K; Ohashi K; Fujii T; Matoba S; Ubara Y
    Case Rep Oncol; 2019; 12(2):391-400. PubMed ID: 31244641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
    Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF inhibition and renal thrombotic microangiopathy.
    Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
    N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab].
    Tomita M; Ochiai M; Shu S; Yamauchi Y; Shihara H; Ogata A; Fujisawa N; Yanai Y; Kamata T; Iehara N
    Nihon Jinzo Gakkai Shi; 2014; 56(5):612-7. PubMed ID: 25130034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
    Zhu X; Wu S; Dahut WL; Parikh CR
    Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.
    Ignoffo RJ
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S21-6. PubMed ID: 15552623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies.
    Lee CS; Alwan LM; Sun X; McLean KA; Urban RR
    J Oncol Pharm Pract; 2016 Dec; 22(6):771-776. PubMed ID: 26447100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nephrotoxicity--proteinuria and hypertension--].
    Ando M
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
    Tanaka H; Takahashi K; Yamaguchi K; Kontani K; Motoki T; Asakura M; Kosaka S; Yokomise H; Houchi H
    Biol Pharm Bull; 2018; 41(4):644-648. PubMed ID: 29607938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.